| |
| |
|
| Insider
Information: |
Belldegrun Arie |
| Relationship: |
Director |
| City: |
Los Angeles |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
2,474,579 |
|
|
Indirect Shares
|
14,159,813 |
|
|
| Direct
Value |
$5,860,124 |
|
|
|
Indirect Value
|
$644,330 |
|
|
| Total
Shares |
16,634,392 |
|
|
| Total
Value |
$6,504,454 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Chem Rx Corporation |
CHRXU |
Director |
2005-10-21 |
106,250 |
|
0 |
Premium* |
|
|
Arno therapeutics Inc |
ARNI |
Director |
2016-08-15 |
3,115 |
2016-08-15 |
3,929,757 |
Premium* |
|
|
Capricor Therapeutics |
CAPR |
Director |
|
0 |
2009-09-24 |
711,420 |
Premium* |
|
|
Kite Pharma, Inc. |
KITE |
Chairman, President an... |
2017-10-03 |
0 |
2017-10-03 |
0 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
|
2024-01-25 |
1,866,859 |
2024-01-25 |
6,703,322 |
Premium* |
|
|
Urogen Pharma Ltd. |
URGN |
Director |
2022-09-14 |
408,693 |
2019-03-27 |
0 |
Premium* |
|
|
Kronos Bio, Inc. |
KRON |
Director |
|
0 |
2020-10-14 |
2,315,314 |
Premium* |
|
|
Ginkgo Bioworks Holdings, Inc |
DNA |
Director |
2022-06-10 |
89,662 |
2022-06-10 |
500,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALLO |
Allogene Therapeutics, In... |
|
• • – |
2024-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
211,973 |
1,866,859 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,282,976 |
1,654,886 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-09-14 |
4 |
OE |
$5.00 |
$800,000 |
D/D |
160,000 |
408,693 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
• • – |
2022-08-31 |
4 |
OE |
$5.00 |
$16,205 |
D/D |
3,241 |
248,693 |
0 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2022-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
70,921 |
89,662 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-03-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,710,121) |
0 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-03-14 |
4 |
A |
$0.00 |
$0 |
I/I |
4,710,121 |
4,710,121 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-03-14 |
4/A |
D |
$0.00 |
$0 |
I/I |
(4,710,120) |
0 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-03-14 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,710,120 |
4,710,120 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2022-01-12 |
4 |
B |
$12.60 |
$1,953,491 |
I/I |
155,039 |
195,039 |
0.01 |
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2021-09-16 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
18,741 |
|
- |
|
| DNA |
Ginkgo Bioworks Holdings,... |
Director |
– • – |
2021-09-16 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
500,000 |
|
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-05-24 |
4 |
OE |
$18.22 |
$6,906,583 |
D/D |
379,066 |
583,034 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2021-03-26 |
4/A |
OE |
$5.00 |
$16,205 |
D/D |
3,241 |
245,452 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
53,635 |
203,968 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2021-03-24 |
4 |
OE |
$5.00 |
$16,205 |
D/D |
3,241 |
245,452 |
0 |
- |
|
| KRON |
Kronos Bio, Inc. |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$4,090,004 |
I/I |
2,739,052 |
2,315,314 |
0 |
- |
|
| KRON |
Kronos Bio, Inc. |
Director |
– • • |
2020-10-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
255,837 |
|
- |
|
| ALLO |
Allogene Therapeutics, In... |
|
– • – |
2020-06-04 |
4 |
B |
$47.00 |
$6,879,954 |
I/I |
146,382 |
1,798,163 |
0.01 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2019-04-26 |
4 |
A |
$0.00 |
$0 |
I/I |
13,413 |
501,663 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2019-04-26 |
4 |
AS |
$0.00 |
$0 |
I/I |
(598,937) |
5,390,415 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2019-03-27 |
4 |
OE |
$4.02 |
$514,560 |
D/D |
128,000 |
212,211 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2019-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
115,333 |
150,333 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Director |
– • – |
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
114,211 |
|
- |
|
| ALLO |
Allogene Therapeutics, In... |
Director |
– • – |
2018-10-15 |
4/A |
B |
$18.00 |
$3,500,010 |
I/I |
194,445 |
1,691,781 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
